Generic entresto launch?

Are you asking about a specific market (e.g., United States, EU, UK) and a current date? Here’s a quick, cautious update:

- As of the latest general knowledge, there isn’t a widely available generic Entresto (sacubitril/valsartan) on the market in major markets yet. Entresto remains protected by patents and regulatory exclusivities, so generic versions would only launch after patent expiry and any related litigation or settlements are resolved.
- The timing of any generic entry depends on patent expiration timelines in each market and any settlements with generic manufacturers. In the U.S., these timelines can extend into the early-to-mid 2030s or later, depending on patent disputes and pediatric exclusivities. Other regions have their own patent/market exclusivity structures that affect timing.

If you want, I can tailor this to a specific market and date and guide you on how to verify the current status:
- In the U.S.: check the FDA Orange Book for sacubitril/valsartan patent/exclusivity listings and any approved generics.
- In the EU/UK: check the corresponding patent and marketing authorization records (and any SPCs) from EMA/ground sources.
- Look for recent announcements from major generics players (e.g., Teva, Viatris, others) or settlement news, which often signal expected launch windows.

Would you like me to look up the current status for a particular country or region? If yes, tell me which market and I’ll outline the latest publicly available information and how to confirm it.